✦ LIBER ✦

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

✍ Scribed by Venderbosch, S.; Nagtegaal, I. D.; Maughan, T. S.; Smith, C. G.; Cheadle, J. P.; Fisher, D.; Kaplan, R.; Quirke, P.; Seymour, M. T.; Richman, S. D.; Meijer, G. A.; Ylstra, B.; Heideman, D. A. M.; de Haan, A. F. J.; Punt, C. J. A.; Koopman, M.

Book ID: 126166711
Publisher: American Association for Cancer Research
Year: 2014
Tongue: English
Weight: 284 KB
Volume: 20
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-14-0332

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6077 A meta-analysis of the CRYSTAL and

6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status

✍ Van Cutsem, E.; Rougier, P.; Köhne, C.; Stroh, C.; Schlichting, M.; Bokemeyer, C 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Ixabepilone plus capecitabine in metasta

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

✍ Henri Roché; Pierfranco Conte; Edith A. Perez; Joseph A. Sparano; Binghe Xu; Jac 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 378 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB